Benson AB, et al. - This retrospective cohort study aimed to explain real-world treatment patterns of gastrointestinal neuroendocrine tumors (GI NET). The authors revealed that 60% of patients, in this study, initiated treatment with somatostatin analogues (SSA) alone or in combination. The relatively long time to discontinuation proposed possible sustained effectiveness and tolerability.